Literature DB >> 21784872

Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response.

Justin R Pritchard1, Luke A Gilbert, Corbin E Meacham, Jennifer L Ricks, Hai Jiang, Douglas A Lauffenburger, Michael T Hemann.   

Abstract

The Bcl-2 family encompasses a diverse set of apoptotic regulators that are dynamically activated in response to various cell-intrinsic and -extrinsic stimuli. An extensive variety of cell culture experiments have identified effects of growth factors, cytokines, and drugs on Bcl-2 family functions, but in vivo studies have tended to focus on the role of one or two particular members in development and organ homeostasis. Thus, the ability of physiologically relevant contexts to modulate canonical dependencies that are likely to be more complex has yet to be investigated systematically. In this study, we report findings derived from a pool-based shRNA assay that systematically and comprehensively interrogated the functional dependence of leukemia and lymphoma cells upon various Bcl-2 family members across many diverse in vitro and in vivo settings. This approach permitted us to report the first in vivo loss of function screen for modifiers of the response to a front-line chemotherapeutic agent. Notably, our results reveal an unexpected role for the extrinsic death pathway as a tissue-specific modifier of therapeutic response. In particular, our findings show that particular tissue sites of tumor dissemination play critical roles in demarcating the nature and extent of cancer cell vulnerabilities and mechanisms of chemoresistance. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784872      PMCID: PMC3165087          DOI: 10.1158/0008-5472.CAN-11-1014

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  The BCL-2 protein family: opposing activities that mediate cell death.

Authors:  Richard J Youle; Andreas Strasser
Journal:  Nat Rev Mol Cell Biol       Date:  2008-01       Impact factor: 94.444

2.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Authors:  Katrien Berns; Hugo M Horlings; Bryan T Hennessy; Mandy Madiredjo; E Marielle Hijmans; Karin Beelen; Sabine C Linn; Ana Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Hauptmann; Roderick L Beijersbergen; Gordon B Mills; Marc J van de Vijver; René Bernards
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

3.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

Authors:  Jing Deng; Nicole Carlson; Kunihiko Takeyama; Paola Dal Cin; Margaret Shipp; Anthony Letai
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

Review 4.  The mighty mouse: genetically engineered mouse models in cancer drug development.

Authors:  Norman E Sharpless; Ronald A Depinho
Journal:  Nat Rev Drug Discov       Date:  2006-08-18       Impact factor: 84.694

5.  Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Authors:  Richard T Williams; Martine F Roussel; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-17       Impact factor: 11.205

6.  Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.

Authors:  Richard T Williams; Willem den Besten; Charles J Sherr
Journal:  Genes Dev       Date:  2007-08-30       Impact factor: 11.361

7.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Authors:  R K Lindemann; A Newbold; K F Whitecross; L A Cluse; A J Frew; L Ellis; S Williams; A P Wiegmans; A E Dear; C L Scott; M Pellegrini; A Wei; V M Richon; Paul A Marks; S W Lowe; M J Smyth; R W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 8.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Authors:  Teru Hideshima; Constantine Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Journal:  Nat Rev Cancer       Date:  2007-08       Impact factor: 60.716

9.  The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest.

Authors:  Thomas Kaufmann; Lin Tai; Paul G Ekert; David C S Huang; Fiona Norris; Ralph K Lindemann; Ricky W Johnstone; Vishva M Dixit; Andreas Strasser
Journal:  Cell       Date:  2007-04-20       Impact factor: 41.582

Review 10.  Bcl-2-regulated apoptosis: mechanism and therapeutic potential.

Authors:  Jerry M Adams; Suzanne Cory
Journal:  Curr Opin Immunol       Date:  2007-07-12       Impact factor: 7.486

View more
  6 in total

1.  Defining principles of combination drug mechanisms of action.

Authors:  Justin R Pritchard; Peter M Bruno; Luke A Gilbert; Kelsey L Capron; Douglas A Lauffenburger; Michael T Hemann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-18       Impact factor: 11.205

2.  CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.

Authors:  Shuang Chen; Yun Dai; Xin-Yan Pei; Jennifer Myers; Li Wang; Lora B Kramer; Mandy Garnett; Daniella M Schwartz; Florence Su; Gary L Simmons; Justin D Richey; Dustin G Larsen; Paul Dent; Robert Z Orlowski; Steven Grant
Journal:  Cancer Res       Date:  2012-06-12       Impact factor: 12.701

3.  Anticancer efficacies of arsenic disulfide through apoptosis induction, cell cycle arrest, and pro-survival signal inhibition in human breast cancer cells.

Authors:  Yuxue Zhao; Bo Yuan; Kenji Onda; Kentaro Sugiyama; Sachiko Tanaka; Norio Takagi; Toshihiko Hirano
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

Review 4.  Using functional genomics to overcome therapeutic resistance in hematological malignancies.

Authors:  Francesca Alvarez-Calderon; Mark A Gregory; James DeGregori
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

5.  Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.

Authors:  J Wan; T Liu; L Mei; J Li; K Gong; C Yu; W Li
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

Review 6.  Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy.

Authors:  Irene Tadeo; Ana P Berbegall; Luis M Escudero; Tomás Alvaro; Rosa Noguera
Journal:  Front Oncol       Date:  2014-03-04       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.